Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity.
Ramachandran
Kavitha
K
Sylvester Cancer Center, University of Miami, Miami, Florida 33136, USA.
Miller
Heather
H
Gordian
Edna
E
Rocha-Lima
Caio
C
Singal
Rakesh
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D001374:Azacitidine / Q000008:administration & dosage / Q000494:pharmacology; D053468:CARD Signaling Adaptor Proteins; D045744:Cell Line, Tumor; D003598:Cytoskeletal Proteins / Q000096:biosynthesis / Q000235:genetics*; D019175:DNA Methylation; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D004357:Drug Synergism; D020868:Gene Silencing; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D011401:Promoter Regions, Genetic; D043823:Taxoids / Q000008:administration & dosage / Q000494:pharmacology; D014162:Transfection; D000093542:Gemcitabine
D053468:CARD Signaling Adaptor Proteins; D003598:Cytoskeletal Proteins; C402202:PYCARD protein, human; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D001374:Azacitidine; D000093542:Gemcitabine